Form 4: Sutro Biopharma Director Acquires Stock Options

Michael Dybbs, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Summary

• Michael Dybbs, a Director at Sutro Biopharma, Inc. (STRO), acquired 10,000 stock options on June 5, 2026.
• The options have an exercise price of $26.09 and are exercisable starting June 5, 2026, with full vesting by June 5, 2027, or the 2027 annual stockholders meeting.
• These options represent the right to buy 10,000 shares of common stock.
• Following this transaction, Dybbs beneficially owns 10,000 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director stock option grant, indicating continued engagement and potential alignment with company performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The options are exercisable relatively soon, with full vesting within approximately one year.

Risks

• The value of the stock options is contingent on the future stock price of Sutro Biopharma, Inc. exceeding the exercise price of $26.09.
• Vesting is subject to continued service to the issuer.

Future Outlook

The vesting schedule for the stock options indicates a near-term expectation of continued service and potential future value realization for the director, contingent on company performance.

Industry Context

StockSavvy.ai notes that insider option grants, particularly to directors, are common in the biopharmaceutical sector as a means of aligning executive interests with shareholder value and incentivizing long-term growth, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive alignment of interests, potentially driving performance. However, the dilutive effect of future share issuance upon exercise should be considered.
• Employees: Standard practice for executive compensation, may not have direct impact.
• Management: Reinforces the incentive structure for key personnel.

Next Steps

• The stock options will vest over time, subject to continued service.
• The director may exercise the options if the stock price exceeds $26.09.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading